Jeffrey Calvin, MD
Neurology · Saint Louis, MONPI 1750764866
Payments from drug & device makers
Across 266 payments — averaging $22.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Supernus Pharmaceuticals, Inc.$602
- Biohaven Pharmaceuticals, Inc.$250
- Pfizer$186
- Biogen$146
- SK Life Science, Inc.$126
- plus $959 from 19 others
What the payments were for
- Food & beverage$6,116100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 192 | $3,847 |
| Supernus Pharmaceuticals, Inc. | 5 | $602 |
| Biohaven Pharmaceuticals, Inc. | 2 | $250 |
| Pfizer | 13 | $186 |
| Biogen | 7 | $146 |
| SK Life Science, Inc. | 2 | $126 |
| EMD Serono, Inc. | 6 | $116 |
| Lilly USA, LLC | 6 | $105 |
| Novartis | 4 | $99 |
| Amgen | 4 | $80 |
| UCB, Inc. | 3 | $75 |
| MDD US Operations, LLC | 3 | $66 |
| Neurelis, Inc. | 3 | $58 |
| Catalyst Pharmaceuticals, Inc. | 2 | $56 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| CSL Behring | 1 | $32 |
| Averitas Pharma Inc. | 2 | $32 |
| Genentech USA, Inc. | 2 | $32 |
| Amneal Pharmaceuticals LLC | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Medtronic | 1 | $27 |
| Argenx US, Inc. | 1 | $27 |
| Grifols USA, LLC | 1 | $23 |
| Impel Pharmaceuticals Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$539
- UBRELVY$472
- NURTEC ODT$250
- XCOPRI$120
How this compares
$6,116 in reported general payments places this provider in the 65th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex Pen (4 Pack)Interferon Beta-1a | 14 | $134,426 |
| VumerityDiroximel Fumarate | 12 | $105,668 |
| CopaxoneGlatiramer Acetate | 16 | $96,852 |
| Emgality PenGalcanezumab-Gnlm | 126 | $89,798 |
| Nurtec OdtRimegepant Sulfate | 49 | $66,909 |
| QuliptaAtogepant | 57 | $62,477 |
| NuplazidPimavanserin Tartrate | 11 | $51,728 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $33,162 |
| UbrelvyUbrogepant | 24 | $30,642 |
| XcopriCenobamate | 11 | $29,597 |
| ReyvowLasmiditan Succinate | 31 | $22,944 |
| EpidiolexCannabidiol (Cbd) | 11 | $19,156 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 21 | $18,302 |
| Glatiramer Acetate | 12 | $17,967 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 184 | $10,009 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $146 | $105,66812 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $42 | $96,85216 claims |
| AbbVieQulipta, Ubrelvy | $3,847 | $93,12081 claims |
| PfizerNurtec Odt | $186 | $66,90949 claims |
| SK Life Science, Inc.Xcopri | $126 | $29,59711 claims |
| Lilly USA, LLCReyvow | $105 | $22,94431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 381 neurology providers in Missouri.
Other neurology in Saint Louis
- Randall BatemanSaint Louis$92.3M
- David HoltzmanSaint Louis$25.2M
- Robert NaismithSaint Louis$13.8M
- Eric McDadeSaint Louis$9.6M
- Robert BucelliSaint Louis$8.5M
- Barbara SniderSaint Louis$7M
- Gregory WuSaint Louis$5.7M
- Barry SingerSaint Louis$3.3M
- Mark TullmanSaint Louis$2.3M
- Suzanne SchindlerSaint Louis$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.